Table 2.
Medical treatment for gastrointestinal complications in ATTRv
Underlying pathology | Symptoms | Available treatments |
---|---|---|
Gastroparesis | Early satiety, nausea and vomiting | D2 receptor antagonists |
Domperidonea | ||
Metoclopramide | ||
Levosulpiridea | ||
Motilin receptor agonists | ||
Erythromycin | ||
5-HT4 agonists | ||
Prucalopride | ||
Ghrelin agonist | ||
Relamorelinb | ||
Small bowel bacterial contamination | Constipation/diarrhoea, diarrhoea | Antibioticsc |
Rifaximin | ||
Metronidazole | ||
Amoxicillin/clavulanic acid | ||
Doxycycline | ||
Probioticsd | ||
Slow transit | Constipation | Osmotic active preparations |
Polyethylene glycol | ||
Picosulphatea | ||
5-HT4 agonists | ||
Linaclotide | ||
Lubiprostonea | ||
Prucalopride | ||
Bile acid malabsorption | Diarrhoea | Bile acid sequestrants |
Cholestyramine (preferably in conjunction with a reduced-fat diet) | ||
Rapid GI transit | Diarrhoea | Opioid receptor agonists |
Loperamide | ||
Somatostatin analogues | ||
Octreotide |
aNot available in all countries
bUnder consideration for approval by the European Medicines Agency
cAccording to local practice; the most effective antibiotic for this indication is not settled
dSubstantial variation in types of probiotics among different countries; most preparations contain strains of Lactobacillus